Data / Form D filings / Tricida, Inc.
Tricida, Inc.: Form D filings
Tricida, Inc., a pharmaceuticals company in South San Francisco, CA, filed 4 Form D notices with the SEC between 2014 and 2017. The latest, on November 15, 2017, reports $57.6 million sold of a $57.6 million offering to 13 investors.
Find out what Tricida, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7000 SHORELINE COURT, SUITE 201, South San Francisco, CA, 94080
- Phone
- (415) 429-7800
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2013
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1595585
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 15, 2017 | New notice | $57,559,996 | $57,559,996 | $0 | 13 | Nov 7, 2017 | sec.gov |
| Jul 25, 2016 | New notice | $55,500,000 | $23,908,857 | $31,591,143 | 6 | Jul 12, 2016 | sec.gov |
| Feb 27, 2015 | New notice | $30,250,000 | $17,141,667 | $13,108,333 | 4 | Feb 13, 2015 | sec.gov |
| Jan 30, 2014 | New notice | $13,164,243 | $4,514,244 | $8,649,999 | 3 | Dec 18, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Edward Hejlek | Executive Officer | |
| Klaus Veitinger | Director | |
| Gerrit Klaerner | Executive Officer, Director | |
| David Hirsch | Director | |
| Jerry Buysse | Executive Officer | |
| Robert Alpern | Director | |
| Sandra Coufal | Director | |
| David Bonita | Director | |
| Wilhelm Stahl | Executive Officer | |
| Claire Lockey | Executive Officer | |
| Geoffrey Parker | Executive Officer |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Nov 13, 2017 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Tricida, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.